

Enhanced plasma H₂S levels associated with fasting blood glucose in Type-2 diabetes mellitus

Pinaki Saha¹, Piyasa Banerjee², Prasenjit Pal¹, Lakshmisona Auddya¹, Santanu Sen³, Tanmay Jyoti Sau⁴, Arun Kumar⁵, Utpal Kumar Biswas⁶

¹Junior Resident, Department of Biochemistry, NRS Medical College, Kolkata, West Bengal, India, ²Research Assistant, Department of Biochemistry, NRS Medical College, Kolkata, West Bengal, India, ³Assistant Professor, Department of Biochemistry, NRS Medical College, Kolkata, West Bengal, India, ⁴Associate Professor, Department of General Medicine, NRS Medical College, Kolkata, West Bengal, India, ⁵Associate Professor, Department of Biochemistry, Manipal College of Medical Sciences, Pokhara, Nepal, ⁶Professor and Head, Department of Biochemistry, NRS Medical College, Kolkata, West Bengal, India

Submitted: 05-05-2015

Revised: 30-06-2015

Published: 01-07-2015

ABSTRACT

Introduction: A number of recent literatures suggest a potential role of H₂S and H₂S modifying agents in the etiology and management of type-2 diabetes mellitus. **Objective:** The current study was aimed to evaluate the plasma levels of H₂S in the patients with type 2 Diabetes mellitus and to find out if there is any relationship of H₂S concentrations with the fasting blood glucose levels. **Methods:** Plasma H₂S levels were measured in sixty two recently diagnosed type 2 diabetic patients and compared with similar number of healthy volunteers as controls. **Results:** The plasma H₂S level in the patients (81.17 ± 16.40 micromol/l) is significantly higher ($P < 0.001$) than the healthy controls (50.69 ± 8.69 micromol/l) and the H₂S levels in plasma have significant positive correlation ($r = 0.359$, $P = 0.004$) with fasting blood glucose levels. **Conclusion:** The present study has elucidated that the patients with type-2 diabetes mellitus are associated with elevated plasma H₂S levels which are well correlated with glucose levels. This reveals a potential role of H₂S modulators towards the management of this non-communicable epidemic disorder.

Key words: Type 2 diabetes mellitus, Plasma H₂S levels, FBG

Access this article online

Website:

<http://nepjol.info/index.php/AJMS>

DOI: 10.3126/ajms.v6i6.12532

BACKGROUND

The prevalence of diabetes mellitus type-2 have drastically increased to several folds in the last two decades.¹ Though several etiological background of this non-communicable epidemic disease has been well explained and being efficiently treated, yet, a number of recent literatures suggested a potential role of H₂S and H₂S modifying agents in the etiology and management of this metabolic disorder.²

Hydrogen sulfide is endogenously produced in the mammalian tissues from the amino acid L-cysteine by the action of two enzymes, cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CSE). Both of these enzymes are dependent on pyridoxal-5'-phosphate. Recent studies have shown a third H₂S-producing enzyme, 3-mercaptopyruvate sulfur transferase (3MST), along with cysteine aminotransferase

(CAT), which produces H₂S in the brain as well as in the vascular endothelium.^{3,4} Expression of CSE or CBS is tissue specific. CSE is expressed mainly in the thoracic aorta, portal vein, ileum, heart, liver, kidney, and vascular smooth muscle, whereas CBS is highly expressed in the central and peripheral nervous systems.⁵⁻⁹ The majority of H₂S is metabolized to sulfate and thiosulfate via oxidative metabolism in mitochondria, while only low levels of H₂S can be converted into less toxic compounds by the cytosolic detoxification pathway. This oxidation is not enzymatically driven, while thiosulfate conversion to sulfate and/or sulfite is catalyzed by thiosulfate cyanide sulfur-transferase (TST).¹⁰ These metabolic products are then expelled within 24 hours via the kidneys, intestinal tract and lungs to maintain the normal levels of H₂S in plasma. Under normal circumstances, H₂S does not accumulate, which means that under physiological conditions, endogenous H₂S is not toxic to cells.

Address for Correspondence:

Dr. Utpal Kumar Biswas, Professor and Head, Department of Biochemistry, NRS Medical College, Kolkata,

Email: drutpalbiswas2010@gmail.com, Phone: +91-9051642109

© Copyright AJMS

Presently it has emerged as a mediator of important physiologic functions in humans.¹¹ Recent reports suggests that the changes in the balance of hydrogen sulfide (H₂S) play an important role in the pathogenesis of β -cell dysfunction that occurs in type 1 and type-2 diabetes. In addition, changes in H₂S homeostasis also play a role in the pathogenesis of endothelial injury, which develop on the basis of chronically or intermittently elevated circulating glucose levels in diabetes. Experimental evidences have been published implicating H₂S overproduction as a causative factor in the pathogenesis of β -cell death in diabetes.^{12,13} Some other experiments have suggested H₂S deficiency due to increased H₂S consumption by hyperglycemic cells, in the pathogenesis of diabetic endothelial dysfunction, diabetic nephropathy, and cardiomyopathy.¹² There is possibility that the modulation of H₂S production may be a potential therapeutic strategy for diabetes mellitus.¹³ This has led researchers to investigate H₂S related substances for treatment of diabetes.^{14,15}

However, very few literatures have reported the plasma levels of H₂S in human. Most of the reports are in the animal model and the H₂S concentrations are reported mainly at the tissue level.^{16,17} Previous studies have also given controversial findings. Some reported that the levels of H₂S in streptozotocin induced diabetic rats is reduced.¹³ Others have found an elevated levels of H₂S in plasma in the similar animal models.¹⁷

Since there is paucity of data in this aspect and no previous report in our population, the aim of our study is to evaluate the plasma levels of H₂S in the patients with type 2 Diabetes mellitus and to find out if there is any relationship of H₂S concentrations with the fasting blood glucose levels.

MATERIALS AND METHODS

This case control study was conducted in the department of Biochemistry and Medicine, NRS Medical College, Kolkata, India. Sixty two recently diagnosed type 2 diabetic patients within 20 to 50 years of age, consisting 30 males and 32 females, were enrolled for the study along with similar number of age matched healthy volunteers as controls (37 males and 25 females). The study was pre approved by the Institutional Ethics Committee. Pregnant mothers, Patients with Type-1 diabetes mellitus and other endocrine disorders, polycystic ovarian disease, renal failure, malignant disease, receiving antioxidant and H₂S modifying agents were excluded from the study.

Sample collection

Fasting blood samples were collected aseptically in heparin containing vials from the patients and healthy controls after obtaining informed consent. Whole blood was used

for estimation of HbA_{1c}. The plasma was separated by centrifugation, immediately used for estimation of H₂S and FBG. Rest is kept stored at 4°C for estimation of other biochemical parameters, done within 48 hours. Buffers and reagents were kept inside appropriate temperature zones in refrigerators.

Measurement of H₂S concentration in plasma

Plasma H₂S levels were estimated following methods described earlier^{13,18,19} with further modification and standardization in our laboratory. This spectrophotometric method involves the reaction of sulfide with N, N-dimethyl-p-phenylenediamine sulfate in the presence of the oxidising agent Fe³⁺ in hydrochloric acid to form methylene blue which is read at 670nm.

Assay procedure

Seventy-five ml of plasma was added to 425 microliter of PBS and 250 microliter of 10% tri-chloroacetic acid in a capped glass tube. Then it was centrifuged at 3000 rpm for 30 minutes. The supernatant was taken in another glass tube and 250 microliter of 1% zinc acetate, 133 microliter of 20 milimolar N, N-dimethyl- p- phenylene diamine sulphate in 7.2 mM HCl, 133 microliter of 30 milimolar FeCl₃ in 1.2 mM of HCl and 60 microliter of 10% NaOH was added, capped and incubated for 10 minutes at room temperature. All samples were assayed in triplicates and the plasma of H₂S levels calculated against a calibration curve prepared using 25-250 micromol/l concentrations of sodium sulfide (NaHS, Sigma-Aldrich, MO, USA) as shown in Figure 1. The intra-assay and inter-assay variation of this method was 7.576 and 3.944 respectively and the maximum sensitivity was up to 25 micromol/l.

Estimation of fasting blood glucose and other biochemical parameters were done using standardized reagent kit.

Statistical analysis

Data were expressed as mean \pm standard deviation (SD), comparison of data was done using unpaired two-tailed Students' t-test and Pearson's correlation, P<0.05 was considered as significant. Statistical analysis was done using Microsoft Office Excel-2007 and SPSS Statistics version 2020.

RESULTS AND DISCUSSION

The clinico-biochemical parameters of the study subjects are depicted in Table 1. The plasma H₂S level in the patients in our study is 81.17 \pm 16.40 micromol/l with the range from 52.50 to 110.83 micromol/l. This was significantly (P< 0.001) higher than age/sex matched healthy controls which is 50.69 \pm 8.69 micromol/l, with a range from 41.67 to 71.67 micromol/l (Table 1 and Figure 2). Plasma H₂S




Figure 1: Standard curve of plasma H₂S assay

levels in the patients as well as control subjects in our study are comparable with earlier studies which is within the range of 10 to 100 micromol/l in human subjects.⁵

Elevated hydrogen sulfide levels in plasma were also reported in patients with proliferative diabetic retinopathy²⁰ as well as patients with cardiovascular disease²¹ cerebral ischaemic damage²² and septic shock²³. M. Yusuf *et al.* has earlier reported that the streptozotocin-induced diabetes in rat is associated with enhanced tissue hydrogen sulfide biosynthesis.¹⁷ The activities of H₂S producing enzymes and the tissue H₂S contents are known to increase under diabetic conditions.²⁴

The other studies have reported reduced levels of H₂S in the plasma as well as in the tissues in diabetes mellitus. Jain *et al.* demonstrated lower circulatory levels of H₂S in type-2 diabetic patients,⁵ but their observations were associated with increased levels of pro-inflammatory cytokines which may have affected the outcome. In another study¹³ Brancalione *et al.* demonstrated impaired H₂S in the non-obese diabetic (NOD) mice.²⁵ Whiteman *et al.* also reported decreased plasma H₂S levels in overweight participants and patients with type-2 diabetes mellitus. They have suggested that adiposity is a major determinant of plasma H₂S levels.²⁶ However, in the current study the subjects were mostly non-obese and non-overweight. Mean body mass index of our patients was within the reference range. So the findings of the current study could not demonstrate whether adiposity plays a role in determination of plasma levels of H₂S in patients suffering from type-2 diabetes.

Measurement of sulfide concentrations in biological materials is difficult due to its volatility, tendency to undergo oxidation, adsorption to glass and rubber and binding to organic molecules (Richardson et al, 2000).^{27,28} In biological tissues and fluids, the sulfide concentrations




Figure 2: Comparison of plasma H₂S levels in patients and controls

Table 1: The clinical and biochemical parameters of the study subjects

Variables	Mean±SD		P value
	Patient	Control	
Age (years)	44.03±5.27	43.63±5.56	
Sex (M/F)	30/32	37/25	
Body mass index (BMI)	24.15±4.09	24.81±2.63	NS
Fasting blood Glucose (mg/dl)	119.14±26.88	79.06±12.64	<0.001*
Post prandial blood Glucose (mg/dl)	176.08±46.26	108.76±11.16	<0.001*
Glycosylated haemoglobin HbA _{1c} (%)	6.85±1.14	3.8±0.34	<0.001*
Plasma H ₂ S level (micromol/l)	81.17±16.40	50.69±8.69	<0.001*

Student's t-test was done, * - significant (P<0.05), with 95% confidence level: NS=Not significant

are typically determined and the concentrations of unionized sulfide can be further calculated from the concentration of dissolved sulfide.^{28,29} A number of analytical techniques have been used for measuring hydrogen sulfide in biological tissues and fluids like blood or plasma including gas chromatography coupled with flame ionizing detection (GC/FID), gas chromatography coupled with flame photometric detection (GC/FPD), iodometric titration, potentiometry with ion selective




Figure 3: Scatter plot showing correlation between plasma H₂S and FBG values in patients (Or) Plasma H₂S levels show significant positive correlation ($r = 0.359$, $P = 0.004$) with fasting blood glucose levels

electrodes (ISE), spectrophotometry and high performance liquid chromatography (HPLC). However, we have used here the methylene blue method with further modifications for estimation of plasma H₂S levels, originally developed by Siegel L M, 1965, and later modified by Stipanuk M H and Beck P W, 1982, Richardson *et al*, Zheng Y. *et al*.^{19,27,31-33} This colorimetric method has limitations because of viscosity and turbidity and a detection limit of 0.25 micromol/l, but this simple colorimetric method used in our study is cost-effective and can be performed in a simple laboratory even at the rural set-up where other sophisticated methods are not feasible.

CONCLUSION

The current study elucidated increased levels of H₂S in type-2 diabetes mellitus and the plasma H₂S levels are significantly correlated with glucose levels. Further study is needed in this direction to establish the role of H₂S modulators towards the management of this non-communicable epidemic disorder.

Limitations of the study

The sample size for the current study was small as it was a pilot study. Further studies are required to validate the results of the current study with large sample size.

REFERENCES

1. Ramachandran A, Snehalata C, Kapur A, Vijay V, Mohan V, Das AK, et al. High Prevalence of Diabetes and Impaired Glucose tolerance in India: National Urban Diabetes Survey. *Diabetologia* 2001; 44:1094-1101.
2. Taniguchi S, Niki I. Significance of Hydrogen Sulfide Production in the Pancreatic β -Cell. *Journal of Pharmacological Sciences* 2011; 116(1):1-5.
3. Shibuya N, Tanaka M, Yoshida M, Ogaswara Y, Togawa T,

Ishii K, et al. 3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain. *Antioxid Redox Signal* 2009; 11(4):703-714.

4. Shibuya N, Mikami Y, Kimura Y, Nagahara N, Kimura H. Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide. *J Biochem* 2009;146(5):623-626.
5. Jain SK, Bull R, Rains JL, Bass PF, Levine SN, Reddy S, et al. Low Levels of Hydrogen Sulfide in the Blood of Diabetes Patients and Streptozotocin-Treated Rats Causes Vascular Inflammation? *Antioxidants and Redox Signalling* 2010; 12(11):1333-1337.
6. Abe K, Kimura H. The possible role of Hydrogen Sulfide as endogenous neurotransmitter. *The Journal of Neuroscience* 1996; 16(3):1066-1071.
7. Hosoki R, Matsuki N, Kimura H. The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. *Biochem Biophys Res Commun* 1997; 237(3): 527-531.
8. Jha S, Calvert JW, Duranski MR, Ramachandran A, Lefer DJ. Hydrogen sulfide attenuates hepatic ischemia reperfusion injury: Role of antioxidant and antiapoptotic signaling. *Am J Physiol Heart Circ Physiol* 2008; 295(2):H801-806.
9. Lefer DJ, Granger DN. Monocyte rolling in early atherosclerosis: genesis: vital role in lesion development. *Circ Res* 1999; 84(11):1353-1355.
10. Caliendo G, Cirino G, Santagada V, Wallace JL. Synthesis and Biological Effects of Hydrogen Sulfide (H₂S): Development of H₂S-Releasing Drugs as Pharmaceuticals. *Journal of Medicinal Chemistry* 2010; 53(17):6275-6286.
11. Li L, Rose P, Moore PK. Hydrogen Sulfide and Cell Signalling. *Annual Review of Pharmacology and Toxicology* 2011; 51:169-187.
12. Szabo C. Roles of Hydrogen Sulfide in the Pathogenesis of Diabetes Mellitus & Its Complications. *Antioxidants & Redox Signaling* 2012; 17(1):68-80.
13. Dutta M, Biswas UK, Chakraborty R, Banerjee P, Roychoudhuri U, Kumar A. Evaluation of plasma H₂S levels and H₂S synthesis in streptozotocin induced Type 2 diabetes-an experimental study based on Swietenia macrophylla seeds. *Asian Pacific Journal of Tropical Biomedicine* 2014; 4(1):S483-S487.
14. Si YF, Wang J, Guan J, Zhou L, Sheng Y, Zhao J. Treatment with hydrogen sulfide alleviates streptozotocin-induced diabetic retinopathy in rats. *Br J Pharmacol* 2013;169(3):619-631.
15. Szabo C. Hydrogen sulphide and its therapeutic potential. *Nat Rev Drug Discov* 2007; 6(11):917-935.

16. Ang AD, Konigstorfer A, Giles GI, Bhatia M. Measuring free tissue sulfide. *Advances in Biological Chemistry* 2012; 2:360-365.
17. Yusuf M, Kwong HBT, Hsu A, Whiteman M, Bhatia M, Moore PK. Streptozotocin-induced diabetes in the rat is associated with enhanced tissue hydrogen sulfide biosynthesis. *Biochem Biophys Res Commun* 2005; 333(4):1146-1152.
18. Ali MY, Whiteman M, Low CM, Moore PK. Hydrogen sulphide reduces insulin secretion from HIT-T15 cells by a K-ATP channel dependent pathway. *J Endocrinol* 2007; 195(1):105-112.
19. Yang Z, Feng L, Junbao DU, Chaoshu T, Guoheng XU, Bin G. Modified methylene blue method for measurement of hydrogen sulfide level in plasma. *Acta Physiologica Sinica*. 2012; 64(6):681-686.
20. Ran R, Du L, Zhang X, Chen X, Fang Y, Li Y, Tian H. Elevated hydrogen sulfide levels in vitreous body and plasma in patients with proliferative diabetic retinopathy. *Retina* 2014; 34(10):2003-2009.
21. Peter EA, Shen X, Shah SH, Pardue S, Glawe JD, Zhang WW, et al. Plasma free H₂S levels are elevated in patients with cardiovascular disease. *Journal of American Heart Association* 2013;2:e000387.
22. Qu K, Christopher PH, Halliwell B, Moore PK, Peter T, Wong H. Hydrogen sulfide is a mediator of cerebral ischaemic damage. *Stroke* 2006;37(3):889-893.
23. Hui Y, Du J, Tang C, Bin G, Jiang H. Changes in arterial hydrogen sulfide (H₂S) content during septic shock and endotoxin shock in rats. *Journal of Infection* 2003; 47(2):155-160.
24. Kaneko Y, Kimura Y, Kimura H, Niki I. L-cysteine and H₂S inhibit insulin release from the pancreatic beta cells. *Diabetes* 2006; 55(5):1391-1397.
25. Brancaleone V, Roviezzo F, Vellecco V, DeGrutolla L, Bucci M and Cirino G. Biosynthesis of H₂S is impaired in non-obese diabetic (NOD) mice. *British Journal of Pharmacology* 2008; 155(5):673-680.
26. Whiteman M, Gooding KM, Whatmore J, Ball CI, Mawson D, Skinner K, et al. Adiposity is a major determinant of plasma levels of the novel vasodilator hydrogen sulfide. *Diabetologia* 2010; 53(8):1722-1726.
27. Richardson CJ, Magee EA, Cummings JH. A new method for determination of sulfide in gastrointestinal contents and whole body by microdistillation and ion chromatography. *Clinica Chimica Acta* 2000; 293:115.
28. Kolluru GK, Shen X, Bir SC, Kevil CG. Hydrogen sulfide chemical biology: Pathophysiological roles and detection. *Nitric oxide* 2013; 35:6-20.
29. Oslon KR. Is hydrogen sulfide a circulating gasotransmitter in vertebrate blood? *Biochimica et Biophysica Acta*. 2009. 1787(7):856-863.
30. Shen X, Patillo CB, Pardue S, Bir SC, Wang R, Kevil CG. Measurement of plasma hydrogen sulfide in vivo and in vitro. *Free Radical Biology & Medicine*. 2011;50(9):1021-1031.
31. Zhao W, Zhang J, Lu Y, Wang R. The vasorelaxant effect of H₂S as a novel endogenous gaseous K(ATP) channel opener. *EMBO J* 2001; 20(21):6008-6016.
32. Siegel LM. A direct microdetermination for sulfide. *Annul Biochem*. 1965;11:126-132.
33. Stipanuk MH, Beck PW. Characterisation of Enzymatic Capacity for cysteine desulphhydration in liver and kidney of the rat. *Biochem J*. 1982; 206(2):267-277.

Authors Contribution:

PS – Designed the study, Data Acquisition, Data Analysis and Drafting of Manuscript. **UKB** – Data Analysis, Drafting of Manuscript, Review of Manuscript. **AK** – Manuscript Preparation, Data Analysis, Review of Manuscript, Final Approval.

Source of Support: Nil, **Conflict of Interest:** None declared.